Tumors exhibiting tumor-infiltrating lymphocytes (TILs), PD-L1 expression, tumor-associated immune cells, potential genomic instability, and a pre-existing antitumoral immune response (“hot” tumors) generally show better responsiveness to immunotherapy. The gene discussed is CD274; the disease is neoplasm.